GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ekso Bionics Holdings Inc (NAS:EKSO) » Definitions » Cash Flow from Investing

Ekso Bionics Holdings (Ekso Bionics Holdings) Cash Flow from Investing : $-0.12 Mil (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Ekso Bionics Holdings Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Ekso Bionics Holdings spent $0.01 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Ekso Bionics Holdings spent $0.01 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Ekso Bionics Holdings Cash Flow from Investing Historical Data

The historical data trend for Ekso Bionics Holdings's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ekso Bionics Holdings Cash Flow from Investing Chart

Ekso Bionics Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 - -0.06 -5.18 -0.16

Ekso Bionics Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.06 -0.02 -0.04 -0.01

Ekso Bionics Holdings Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Ekso Bionics Holdings's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Ekso Bionics Holdings's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ekso Bionics Holdings  (NAS:EKSO) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Ekso Bionics Holdings's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-0.01 Mil. It means Ekso Bionics Holdings spent $0.01 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Ekso Bionics Holdings's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Ekso Bionics Holdings gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Ekso Bionics Holdings's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Ekso Bionics Holdings spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Ekso Bionics Holdings's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Ekso Bionics Holdings gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Ekso Bionics Holdings's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Ekso Bionics Holdings spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Ekso Bionics Holdings's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Ekso Bionics Holdings gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Ekso Bionics Holdings's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Ekso Bionics Holdings paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Ekso Bionics Holdings's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Ekso Bionics Holdings paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Ekso Bionics Holdings's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Ekso Bionics Holdings paid $0.00 Mil for other investing activities.


Ekso Bionics Holdings Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Ekso Bionics Holdings's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Ekso Bionics Holdings (Ekso Bionics Holdings) Business Description

Traded in Other Exchanges
Address
101 Glacier Point, Suite A, San Rafael, CA, USA, 94901
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The regions company operates in are the Americas, EMEA, and APAC.
Executives
Jerome Wong officer: Interim CFO C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Scott G. Davis officer: President & COO C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Steven Sherman director
Jason C Jones officer: VP of Product Development EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
John Glenn officer: Chief Financial Officer 7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577
Lathan Corinna director 140 KENDRICK STREET, NEEDHAM MA 02494
William R Shaw officer: See Remarks 1414 HARBOUR WAY SOUTH, SUITE 1201, C/O EKSO BIONICS HOLDINGS, INC., RICHMOND CA 94804
Rhonda A. Wallen director C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Mary Ann Cloyd director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Combest Development (hong Kong) Ltd 10 percent owner ROOM 2210, CC WU BUILDING 302, HENNESSY ROAD, WAN CHAI, HONG KONG K3 999077
Jack Peurach director, officer: Chief Executive Officer 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Thomas A Schreck director 10240 BUBB RD, CUPERTINO CA 95014
Puissance Capital Management Lp 10 percent owner 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Christian Babini officer: VP of Sales, Americas C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1, RICHMOND CA 94804
Puissance Cross-border Opportunities Ii Llc 10 percent owner C/O PUISSANCE CAPITAL FUND (GP) LLC, 950 THIRD AVENUE, NEW YORK NY 10022